17 Mar Nearly 100 Organizations and Experts Urge HHS Secretary Xavier Becerra to Reject Xtandi March-In Petition
WASHINGTON, D.C. (March 17) – In a letter transmitted today, the Bayh-Dole Coalition and nearly 100 prominent academic and private sector innovation experts and organizations, public policy associations, and legal scholars urged U.S. Department of Health and Human Services Secretary Xavier Becerra to reject the latest march-in petition on prostate cancer drug Xtandi.
“The petition flagrantly misrepresents the meaning of the Bayh-Dole Act,” said Joseph P. Allen, the executive director of the Coalition. “The Act’s purpose is to facilitate the commercialization of technologies developed from federally funded inventions — not to serve as a backdoor for price controls of successfully developed inventions.”
Prominent signatories of the letter include Katherine Bayh, wife of the late Sen. Birch Bayh, John Hamre, Ph.D., former deputy secretary at the U.S. Department of Defense, and former top academic innovation officials from Yale, Stanford, MIT, and more.
“We look forward to engaging with Sec. Becerra and his team on this critical issue,” said Allen. “The United States’ global competitiveness and world-leading innovation system are at stake.”
About the Bayh-Dole Coalition: The Bayh-Dole Coalition is a diverse group of research and scientific organizations, as well as those directly involved in commercializing new products, dedicated to protecting the Bayh-Dole Act and educating policymakers about the positive impacts of the legislation.
(202) 471-4228 ext. 124